Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCU-i4 is a small molecule inhibitor of the mitochondrial calcium uniporter (MCU), a highly selective calcium channel located in the inner mitochondrial membrane. MCU facilitates the transport of calcium ions from the cytosol into the mitochondrial matrix, where moderate calcium levels stimulate ATP production and cell growth. In various cancers, including breast cancer, MCU is frequently overexpressed, leading to enhanced mitochondrial calcium uptake that supports rapid cancer cell proliferation and metabolic demands. By inhibiting MCU, MCU-i4 reduces mitochondrial calcium levels, thereby suppressing ATP production and inducing cell death. Research has specifically demonstrated its efficacy in BT474 breast cancer cell lines, highlighting its potential as a targeted antineoplastic agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MCU-i4.